{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:11:44Z","timestamp":1792951904567,"version":"4.5.0"},"reference-count":250,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02609-6","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:27:03Z","timestamp":1773890823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges"],"prefix":"10.1186","volume":"25","author":[{"given":"Kohei","family":"Okuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Yanamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Leo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2609_CR1","first-page":"42","volume":"11","author":"A Barsouk","year":"2023","unstructured":"Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11:42.","journal-title":"Med Sci (Basel)"},{"key":"2609_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.","journal-title":"Nat Rev Dis Primers"},{"issue":"10212","key":"2609_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B de Burtness Jr","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"key":"2609_CR4","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1200\/JCO.23.02625","volume":"42","author":"M Dzienis","year":"2024","unstructured":"Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, et al. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent \/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. J Clin Oncol. 2024;42:2989\u201399.","journal-title":"J Clin Oncol"},{"key":"2609_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40487-023-00226-7","volume":"11","author":"S Zheng","year":"2023","unstructured":"Zheng S, Feng Y, Li C, Zhang J, Xie K. Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncol Ther. 2023;11:185\u201398.","journal-title":"Oncol Ther"},{"key":"2609_CR6","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/bjc.2013.645","volume":"109","author":"HB Jie","year":"2013","unstructured":"Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109:2629\u201335.","journal-title":"Br J Cancer"},{"key":"2609_CR7","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1158\/1078-0432.CCR-07-1403","volume":"13","author":"L Strauss","year":"2007","unstructured":"Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301\u201311.","journal-title":"Clin Cancer Res"},{"key":"2609_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2609_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet. 2019;393:156\u201367.","journal-title":"Lancet"},{"key":"2609_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"2609_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956\u201365.","journal-title":"Lancet Oncol"},{"key":"2609_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002998","volume":"9","author":"J Guigay","year":"2021","unstructured":"Guigay J, Lee KW, Patel MR, Daste A, Wong DJ, Goel S, et al. Avelumab for platinum-ineligible\/refractory recurrent and\/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2021;9:e002998.","journal-title":"J Immunother Cancer"},{"key":"2609_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092691","volume":"12","author":"C Borel","year":"2020","unstructured":"Borel C, Jung AC, Burgy M. Immunotherapy breakthroughs in the treatment of recurrent or metastatic head and neck squamous cell carcinoma. Cancers (Basel). 2020;12:2691.","journal-title":"Cancers (Basel)"},{"key":"2609_CR14","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/JCO.22.00332","volume":"41","author":"RI Haddad","year":"2023","unstructured":"Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol. 2023;41:2166\u201380.","journal-title":"J Clin Oncol"},{"key":"2609_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","volume":"34","author":"A Psyrri","year":"2023","unstructured":"Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023;34:262\u201374.","journal-title":"Ann Oncol"},{"key":"2609_CR16","doi-asserted-by":"publisher","first-page":"1128176","DOI":"10.3389\/fonc.2023.1128176","volume":"13","author":"S Wiegand","year":"2023","unstructured":"Wiegand S, Wichmann G, Vogt J, Vogel K, Franke A, Kuhnt T, et al. Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial. Front Oncol. 2023;13:1128176.","journal-title":"Front Oncol"},{"key":"2609_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2","volume":"43","author":"J Bourhis","year":"2025","unstructured":"Bourhis J, Auperin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, et al. NIVOPOSTOP (GORTEC 2018-01): a phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. J Clin Oncol. 2025;43:17_suppl.","journal-title":"J Clin Oncol"},{"key":"2609_CR18","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12:7348.","journal-title":"Nat Commun"},{"key":"2609_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med. 2025;393:37\u201350.","journal-title":"N Engl J Med"},{"key":"2609_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"2609_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","volume":"147","author":"R Masarwy","year":"2021","unstructured":"Masarwy R, Kampel L, Horowitz G, Gutfeld O, Muhanna N. Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021;147:871\u20138.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2609_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"2609_CR23","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","volume":"18","author":"KJ Harrington","year":"2017","unstructured":"Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104\u201315.","journal-title":"Lancet Oncol"},{"key":"2609_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313\u201322.","journal-title":"Nat Rev Cancer"},{"key":"2609_CR25","unstructured":"Dietz A. ADRISK: pembrolizumab plus adjuvant chemoradiation in HNSCC. VJOncology. 2025 Oct 18. Available from https:\/\/www.vjoncology.com\/video\/prn1pad5wmk-adrisk-pembrolizumab-plus-adjuvant-chemoradiation-in-hnscc\/. [Accessed 6 Nov 2025]."},{"key":"2609_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"2609_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00153","volume":"2","author":"S Demaria","year":"2012","unstructured":"Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153.","journal-title":"Front Oncol"},{"key":"2609_CR28","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"key":"2609_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"key":"2609_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0583-3","volume":"7","author":"JD Schoenfeld","year":"2019","unstructured":"Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019;7:112.","journal-title":"J Immunother Cancer"},{"key":"2609_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2478\/raon-2020-0060","volume":"54","author":"G Plavc","year":"2020","unstructured":"Plavc G, Strojan P. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials. Radiol Oncol. 2020;54:377\u201393.","journal-title":"Radiol Oncol"},{"key":"2609_CR32","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"2609_CR33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, et al. NCCN Guidelines\u00ae Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024;22:582\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"2609_CR34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers16071440","volume":"16","author":"S Casagrande","year":"2024","unstructured":"Casagrande S, Sopetto GB, Bertalot G, Bortolotti R, Racanelli V, Caffo O, et al. Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations. Cancers (Basel). 2024;16:1440.","journal-title":"Cancers (Basel)"},{"key":"2609_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022;13:779691.","journal-title":"Front Immunol"},{"key":"2609_CR36","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","volume":"25","author":"LK Mell","year":"2024","unstructured":"Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, et al. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial. Lancet Oncol. 2024;25:1576\u201388.","journal-title":"Lancet Oncol"},{"key":"2609_CR37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","volume":"9","author":"M Spaas","year":"2023","unstructured":"Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F, et al. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9:1205\u201313.","journal-title":"JAMA Oncol"},{"issue":"12","key":"2609_CR38","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"key":"2609_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","volume":"74","author":"R Rubino","year":"2021","unstructured":"Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, et al. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. Endocrine. 2021;74:172\u20139.","journal-title":"Endocrine"},{"key":"2609_CR40","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","volume":"32","author":"CN Owen","year":"2021","unstructured":"Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021;32:917\u201325.","journal-title":"Ann Oncol"},{"key":"2609_CR41","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","volume":"33","author":"RL Ferris","year":"2015","unstructured":"Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:3293\u2013304.","journal-title":"J Clin Oncol"},{"key":"2609_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720951","volume":"11","author":"M Olmos","year":"2021","unstructured":"Olmos M, Glajzer J, B\u00fcntemeyer TO, Frohwitter G, Ries J, Eckstein M, et al. Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response. Front Oncol. 2021;11:720951.","journal-title":"Front Oncol"},{"key":"2609_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970823","volume":"13","author":"M Olmos","year":"2022","unstructured":"Olmos M, Lutz R, B\u00fcntemeyer TO, Glajzer J, Nobis CP, Ries J, et al. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature. Front Immunol. 2022;13:970823.","journal-title":"Front Immunol"},{"key":"2609_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105589","volume":"123","author":"S Cabezas-Camarero","year":"2021","unstructured":"Cabezas-Camarero S, Alonso-Ovies A, Merino-Men\u00e9ndez S, Cabrera-Mart\u00edn MN, Plaza-Hern\u00e1ndez JC, P\u00e9rez-Segura P. Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer. Oral Oncol. 2021;123:105589.","journal-title":"Oral Oncol"},{"key":"2609_CR45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/EDBK_238339","volume":"39","author":"K Lauber","year":"2019","unstructured":"Lauber K, Dunn L. Immunotherapy mythbusters in head and neck cancer: the abscopal effect and pseudoprogression. Am Soc Clin Oncol Educ Book. 2019;39:352\u201363.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2609_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0182.","journal-title":"Science"},{"key":"2609_CR47","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal Replacement of Tumor-Specific T Cells Following PD-1 Blockade. Nat Med. 2019;25:1251\u20139.","journal-title":"Nat Med"},{"key":"2609_CR48","first-page":"5140","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter. Phase II Trial Clin Cancer Res. 2020;26:5140\u201352.","journal-title":"Phase II Trial Clin Cancer Res"},{"key":"2609_CR49","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, et al. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022;28:1345\u201352.","journal-title":"Clin Cancer Res"},{"key":"2609_CR50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hed.26935","volume":"44","author":"N Amin","year":"2022","unstructured":"Amin N, Maroun CA, El Asmar M, Alkhatib HH, Guller M, Herberg ME, et al. Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review. Head Neck. 2022;44:562\u201371.","journal-title":"Head Neck"},{"key":"2609_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566315","volume":"10","author":"DJ Merlino","year":"2020","unstructured":"Merlino DJ, Johnson JM, Tuluc M, Gargano S, Stapp R, Harshyne L Jr, et al. Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect. Front Oncol. 2020;10:566315.","journal-title":"Front Oncol"},{"key":"2609_CR52","doi-asserted-by":"publisher","first-page":"1189752","DOI":"10.3389\/fimmu.2023.1189752","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang K, Gui L, Lu H, He X, Li D, Liu C, et al. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas. Front Immunol. 2023;14:1189752.","journal-title":"Front Immunol"},{"key":"2609_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1581530","volume":"8","author":"S Allen","year":"2019","unstructured":"Allen S, Smyth MJ, Teng MWL. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology. 2019;8:e1581530.","journal-title":"Oncoimmunology"},{"key":"2609_CR54","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655\u201361.","journal-title":"Nat Med"},{"key":"2609_CR55","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24:1649\u201354.","journal-title":"Nat Med"},{"key":"2609_CR56","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29:1861\u20138.","journal-title":"Ann Oncol"},{"key":"2609_CR57","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","volume":"25","author":"JS O'Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019;25:5743\u201351.","journal-title":"Clin Cancer Res"},{"key":"2609_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003026","volume":"10","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10:e003026.","journal-title":"J Immunother Cancer"},{"key":"2609_CR59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40425-019-0572-6","volume":"7","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, et al. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019;7:87.","journal-title":"J Immunother Cancer"},{"key":"2609_CR60","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018;33:843-52.e4.","journal-title":"Cancer Cell"},{"key":"2609_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106309","volume":"138","author":"Y Robbins","year":"2023","unstructured":"Robbins Y, Friedman J, Redman J, Sievers C, Lassoued W, Gulley JL, et al. Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer. Oral Oncol. 2023;138:106309.","journal-title":"Oral Oncol"},{"key":"2609_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002899","volume":"9","author":"A Hazini","year":"2021","unstructured":"Hazini A, Fisher K, Seymour L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer. 2021;9:e002899.","journal-title":"J Immunother Cancer"},{"key":"2609_CR63","doi-asserted-by":"publisher","first-page":"1285895","DOI":"10.3389\/fimmu.2023.1285895","volume":"14","author":"K Amrane","year":"2024","unstructured":"Amrane K, Le Meur C, Besse B, Hemon P, Le Noac\u2019h P, Pradier O, et al. HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker. Front Immunol. 2024;14:1285895.","journal-title":"Front Immunol"},{"key":"2609_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106570","volume":"146","author":"MA Rainey","year":"2023","unstructured":"Rainey MA, Allen CT, Craveiro M. Egress of resident memory T cells from tissue with neoadjuvant immunotherapy: implications for systemic anti-tumor immunity. Oral Oncol. 2023;146:106570.","journal-title":"Oral Oncol"},{"key":"2609_CR65","doi-asserted-by":"crossref","unstructured":"van Poelgeest MIE, Kortekaas KE, van Doorn HC, Oonk M, Nijman HW, Boere I, et al. APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma-a multicenter, single-arm, phase II, clinical proof-of-concept study. Int J Gynecol Cancer. 2024:ijgc-2024\u2013005523.","DOI":"10.1136\/ijgc-2024-005523"},{"key":"2609_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0700-z","volume":"21","author":"MS Pelster","year":"2020","unstructured":"Pelster MS, Amaria RN. Neoadjuvant immunotherapy for locally advanced melanoma. Curr Treat Options Oncol. 2020;21:10.","journal-title":"Curr Treat Options Oncol"},{"key":"2609_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.951137","volume":"13","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Deng D, Pan C, Ren J, Wei T, Wu Z, et al. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy. Front Immunol. 2022;13:951137.","journal-title":"Front Immunol"},{"key":"2609_CR68","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-024-01813-w","volume":"26","author":"N Zhang","year":"2024","unstructured":"Zhang N, Huang Y, Wang G, Xiang Y, Jing Z, Zeng J, et al. Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer. Breast Cancer Res. 2024;26:64.","journal-title":"Breast Cancer Res"},{"key":"2609_CR69","doi-asserted-by":"publisher","first-page":"7695","DOI":"10.1038\/s41467-024-52098-8","volume":"15","author":"AL Eerkens","year":"2024","unstructured":"Eerkens AL, Brummel K, Vledder A, Paijens ST, Requesens M, Loiero D, et al. Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study. Nat Commun. 2024;15:7695.","journal-title":"Nat Commun"},{"issue":"10","key":"2609_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003771","volume":"18","author":"C Abbosh","year":"2021","unstructured":"Abbosh C, Swanton C. ctDNA: an emerging neoadjuvant biomarker in resectable solid tumors. PLoS Med. 2021;18(10):e1003771.","journal-title":"PLoS Med"},{"key":"2609_CR71","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30:1023\u201334.","journal-title":"Nat Med"},{"key":"2609_CR72","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/cancers12113382","volume":"12","author":"T Noguchi","year":"2020","unstructured":"Noguchi T, Iwahashi N, Sakai K, Matsuda K, Matsukawa H, Toujima S, et al. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact. Cancers (Basel). 2020;12:3382.","journal-title":"Cancers (Basel)"},{"key":"2609_CR73","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00262-024-03687-5","volume":"73","author":"L Yi","year":"2024","unstructured":"Yi L, Xu Z, Ma T, Wang C, Wei P, Xiao B, et al. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC. Cancer Immunol Immunother. 2024;73:99.","journal-title":"Cancer Immunol Immunother"},{"key":"2609_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","volume":"3","author":"AA Tarhini","year":"2015","unstructured":"Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.","journal-title":"J Immunother Cancer"},{"key":"2609_CR75","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.1002\/cam4.5918","volume":"12","author":"Y Hu","year":"2023","unstructured":"Hu Y, Li S, Xiao H, Xiong Y, Lu X, Yang X, et al. Distinct circulating cytokine\/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer. Cancer Med. 2023;12:12234\u201352.","journal-title":"Cancer Med"},{"key":"2609_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001698","volume":"9","author":"Z Yin","year":"2021","unstructured":"Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, et al. Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer. 2021;9:e001698.","journal-title":"J Immunother Cancer"},{"key":"2609_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188624","volume":"1876","author":"AS Pathania","year":"2021","unstructured":"Pathania AS, Prathipati P, Challagundla KB. New insights into exosome mediated tumor-immune escape: clinical perspectives and therapeutic strategies. Biochim Biophys Acta Rev Cancer. 2021;1876:188624.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2609_CR78","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.15252\/emmm.201606798","volume":"8","author":"J Goveia","year":"2016","unstructured":"Goveia J, Pircher A, Conradi LC, Kalucka J, Lagani V, Dewerchin M, et al. Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol Med. 2016;8:1134\u201342.","journal-title":"EMBO Mol Med"},{"key":"2609_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00507-3","volume":"11","author":"W Wang","year":"2023","unstructured":"Wang W, Rong Z, Wang G, Hou Y, Yang F, Qiu M. Cancer metabolites: promising biomarkers for cancer liquid biopsy. Biomark Res. 2023;11:66.","journal-title":"Biomark Res"},{"key":"2609_CR80","doi-asserted-by":"publisher","first-page":"26026","DOI":"10.1038\/s41598-024-76982-x","volume":"14","author":"\u00c1 Marcos Rubio","year":"2024","unstructured":"Marcos Rubio \u00c1, Oh S, Roelandt S, Stevens D, Van Damme E, Vermaelen K, et al. Defining the optimal setting for transcriptomic analyses on blood samples for response prediction in immunotherapy-treated NSCLC patients. Sci Rep. 2024;14:26026.","journal-title":"Sci Rep"},{"key":"2609_CR81","doi-asserted-by":"crossref","unstructured":"Zhang L, Hou L, Wu J, Li C, Hu T, Zhu C, et al. Peripheral blood mononuclear cells (PBMCs), an ideal liquid biopsy approach to evaluate systematic immunity and predict response of neoadjuvant chemo-immunotherapy in resectable NSCLC. J Clin Oncol. 40(16_suppl):e20618.","DOI":"10.1200\/JCO.2022.40.16_suppl.e20618"},{"key":"2609_CR82","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13058-024-01883-w","volume":"26","author":"BV Sinn","year":"2024","unstructured":"Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, et al. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. 2024;26:138.","journal-title":"Breast Cancer Res"},{"key":"2609_CR83","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","volume":"9","author":"AN Niemeijer","year":"2018","unstructured":"Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:4664.","journal-title":"Nat Commun"},{"key":"2609_CR84","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.119.229781","volume":"61","author":"N Pandit-Taskar","year":"2020","unstructured":"Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O\u2019Donoghue JA, et al. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. J Nucl Med. 2020;61:512\u20139.","journal-title":"J Nucl Med"},{"key":"2609_CR85","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586\u201392.","journal-title":"Clin Pharmacol Ther"},{"key":"2609_CR86","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29:1853\u201360.","journal-title":"Ann Oncol"},{"key":"2609_CR87","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386:1973\u201385.","journal-title":"N Engl J Med"},{"key":"2609_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107151","volume":"161","author":"Z An","year":"2025","unstructured":"An Z, Zhang X, Wang Z, Wusiman D, Zhao X, Li L, et al. The characterization of tumor immune microenvironment after neoadjuvant immunotherapy in head and neck squamous cell cancer using multiplex immunohistochemistry. Oral Oncol. 2025;161:107151.","journal-title":"Oral Oncol"},{"key":"2609_CR89","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/cncr.34930","volume":"129","author":"SA Patel","year":"2023","unstructured":"Patel SA, Gibson MK, Deal A, Sheth S, Heiling H, Johnson SM, et al. A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma. Cancer. 2023;129:3381\u20139.","journal-title":"Cancer"},{"key":"2609_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112200","volume":"134","author":"J Li","year":"2024","unstructured":"Li J, Luo Z, Jiang S, Li J. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous carcinoma: a narrative review. Int Immunopharmacol. 2024;134:112200.","journal-title":"Int Immunopharmacol"},{"key":"2609_CR91","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1002\/cncr.33780","volume":"127","author":"CC Foster","year":"2021","unstructured":"Foster CC, Couey MA, Kochanny SE, Khattri A, Acharya RK, Tan YC, et al. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer. 2021;127:4565\u201373.","journal-title":"Cancer"},{"key":"2609_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7370","volume":"13","author":"AE Alnemri","year":"2024","unstructured":"Alnemri AE, Tekumalla S, Moroco AE, Vathiotis I, Tuluc M, Gargano S, et al. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma. Cancer Med. 2024;13:e7370.","journal-title":"Cancer Med"},{"issue":"4","key":"2609_CR93","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","volume":"34","author":"M Frelaut","year":"2020","unstructured":"Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E. Pseudoprogression and hyperprogression as new forms of response to immunotherapy. BioDrugs. 2020;34(4):463\u201376.","journal-title":"BioDrugs"},{"key":"2609_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2023.100036","volume":"6","author":"R Kessler","year":"2023","unstructured":"Kessler R, Subramanya P. Immune-related adverse events following checkpoint inhibitor treatment in head and neck cancers: a comprehensive review. Oral Oncol Rep. 2023;6:100036.","journal-title":"Oral Oncol Rep"},{"key":"2609_CR95","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell. 2016;167:1540-54.e12.","journal-title":"Cell"},{"key":"2609_CR96","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","volume":"1","author":"L Zitvogel","year":"2012","unstructured":"Zitvogel L, Kroemer G. Targeting PD-1\/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223\u20135.","journal-title":"Oncoimmunology"},{"key":"2609_CR97","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8:1136.","journal-title":"Nat Commun"},{"key":"2609_CR98","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189\u201399.","journal-title":"N Engl J Med"},{"key":"2609_CR99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"2609_CR100","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/0008-5472.CAN-23-2006","volume":"84","author":"J Yang","year":"2024","unstructured":"Yang J, Liu Q, Shyr Y. A large-scale meta-analysis reveals positive feedback between macrophages and T cells that sensitizes tumors to immunotherapy. Cancer Res. 2024;84:626\u201338.","journal-title":"Cancer Res"},{"key":"2609_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"key":"2609_CR102","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/1078-0432.CCR-19-2209","volume":"26","author":"J Friedman","year":"2020","unstructured":"Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, et al. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020;26:679\u201389.","journal-title":"Clin Cancer Res"},{"key":"2609_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107213","volume":"162","author":"K Okuyama","year":"2025","unstructured":"Okuyama K, Yanamoto S. Comment on \u201cThe characterization of tumor immune microenvironment after neoadjuvant immunotherapy in head and neck squamous cell cancer using multiplex immunohistochemistry.\u201d Oral Oncol. 2025;162:107213.","journal-title":"Oral Oncol"},{"key":"2609_CR104","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12967-024-05409-y","volume":"22","author":"H Sadeghirad","year":"2024","unstructured":"Sadeghirad H, Monkman J, Tan CW, Liu N, Yunis J, Donovan ML, et al. Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. J Transl Med. 2024;22:677.","journal-title":"J Transl Med"},{"key":"2609_CR105","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022;185:2918-35.e29.","journal-title":"Cell"},{"key":"2609_CR106","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161400","volume":"132","author":"JM Redman","year":"2022","unstructured":"Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, et al. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-\u03b2 blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2022;132:e161400.","journal-title":"J Clin Invest"},{"key":"2609_CR107","doi-asserted-by":"crossref","unstructured":"Oliveira G, Egloff AM, Afeyan AB, Wolff JO, Zeng Z, Chernock RD, et al. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci Immunol. 2023;8:eadf4968.","DOI":"10.1126\/sciimmunol.adf4968"},{"key":"2609_CR108","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1158\/2159-8290.CD-22-0851","volume":"13","author":"AM van der Leun","year":"2023","unstructured":"van der Leun AM, Traets JJH, Vos JL, Elbers JBW, Patiwael S, Qiao X, et al. Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment. Cancer Discov. 2023;13:2212\u201327.","journal-title":"Cancer Discov"},{"key":"2609_CR109","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","volume":"28","author":"A Obradovic","year":"2022","unstructured":"Obradovic A, Graves D, Korrer M, Wang Y, Roy S, Naveed A, et al. Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. Clin Cancer Res. 2022;28:2094\u2013109.","journal-title":"Clin Cancer Res"},{"key":"2609_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225716","volume":"13","author":"DT Xing","year":"2021","unstructured":"Xing DT, Khor R, Gan H, Wada M, Ermongkonchai T, Ng SP. Recent research on combination of radiotherapy with targeted therapy or immunotherapy in head and neck squamous cell carcinoma: a review for radiation oncologists. Cancers (Basel). 2021;13:5716.","journal-title":"Cancers (Basel)"},{"key":"2609_CR111","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281\u201393.","journal-title":"Radiother Oncol"},{"key":"2609_CR112","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","volume":"16","author":"EB Golden","year":"2015","unstructured":"Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795\u2013803.","journal-title":"Lancet Oncol"},{"key":"2609_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171559","volume":"12","author":"R Marconi","year":"2017","unstructured":"Marconi R, Strolin S, Bossi G, Strigari L. A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger? PLoS ONE. 2017;12:e0171559.","journal-title":"PLoS ONE"},{"key":"2609_CR114","first-page":"1462","volume":"62","author":"R Ganss","year":"2002","unstructured":"Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62:1462\u201370.","journal-title":"Cancer Res"},{"key":"2609_CR115","first-page":"5150","volume":"56","author":"D Hallahan","year":"1996","unstructured":"Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 1996;56:5150\u20135.","journal-title":"Cancer Res"},{"key":"2609_CR116","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","volume":"181","author":"S Matsumura","year":"2008","unstructured":"Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181:3099\u2013107.","journal-title":"J Immunol"},{"key":"2609_CR117","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1269\/jrr.11079","volume":"52","author":"K Shibuya","year":"2011","unstructured":"Shibuya K, Tsushima Y, Horisoko E, Noda SE, Taketomi-Takahashi A, Ohno T, et al. Blood flow change quantification in cervical cancer before and during radiation therapy using perfusion CT. J Radiat Res. 2011;52:804\u201311.","journal-title":"J Radiat Res"},{"key":"2609_CR118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1011252","volume":"20","author":"J K\u00f6ry","year":"2024","unstructured":"K\u00f6ry J, Narain V, Stolz BJ, Kaeppler J, Markelc B, Muschel RJ, et al. Enhanced perfusion following exposure to radiotherapy: A theoretical investigation. PLoS Comput Biol. 2024;20:e1011252.","journal-title":"PLoS Comput Biol"},{"key":"2609_CR119","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1667\/RR2773.1","volume":"177","author":"HJ Park","year":"2012","unstructured":"Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012;177:311\u201327.","journal-title":"Radiat Res"},{"key":"2609_CR120","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1667\/0033-7587(2000)153[0398:CIBPAH]2.0.CO;2","volume":"153","author":"J Bussink","year":"2000","unstructured":"Bussink J, Kaanders JHAM, Rijken PFJW, Raleigh JA, Kogel AJVd. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res. 2000;153:398\u2013404.","journal-title":"Radiat Res"},{"key":"2609_CR121","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clon.2019.04.006","volume":"31","author":"D Xing","year":"2019","unstructured":"Xing D, Siva S, Hanna GG. The abscopal effect of stereotactic radiotherapy and immunotherapy: fool\u2019s gold or el dorado? Clin Oncol. 2019;31:432\u201343.","journal-title":"Clin Oncol"},{"key":"2609_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010079","volume":"12","author":"J Kabiljo","year":"2019","unstructured":"Kabiljo J, Harpain F, Carotta S, Bergmann M. Radiotherapy as a backbone for novel concepts in cancer immunotherapy. Cancers (Basel). 2019;12:79.","journal-title":"Cancers (Basel)"},{"key":"2609_CR123","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00335-018-9777-0","volume":"29","author":"KJ McKelvey","year":"2018","unstructured":"McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mamm Genome. 2018;29:843\u201365.","journal-title":"Mamm Genome"},{"key":"2609_CR124","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002485","volume":"9","author":"R Leidner","year":"2021","unstructured":"Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 2021;9:e002485.","journal-title":"J Immunother Cancer"},{"key":"2609_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7:258.","journal-title":"Signal Transduct Target Ther"},{"key":"2609_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","volume":"9","author":"RL Ferris","year":"2021","unstructured":"Ferris RL, Spanos WC, Leidner R, Gon\u00e7alves A, Martens UM, Kyi C, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021;9:e002568.","journal-title":"J Immunother Cancer"},{"key":"2609_CR127","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/09553002.2019.1623429","volume":"95","author":"EC Ko","year":"2019","unstructured":"Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019;95:936\u20139.","journal-title":"Int J Radiat Biol"},{"key":"2609_CR128","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39:644\u201355.","journal-title":"Trends Immunol"},{"key":"2609_CR129","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/CCO.0000000000000628","volume":"32","author":"J Biau","year":"2020","unstructured":"Biau J, Bourhis J. Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives? Curr Opin Oncol. 2020;32:196\u2013202.","journal-title":"Curr Opin Oncol"},{"key":"2609_CR130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102611118","volume":"118","author":"DM Lussier","year":"2021","unstructured":"Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A. 2021;118:e2102611118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2609_CR131","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","volume":"25","author":"W Yang","year":"2019","unstructured":"Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25:767\u201375.","journal-title":"Nat Med"},{"key":"2609_CR132","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1329071","volume":"6","author":"M Kikuchi","year":"2017","unstructured":"Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, et al. Preclinical immunoPET\/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology. 2017;6:e1329071.","journal-title":"Oncoimmunology"},{"key":"2609_CR133","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3892\/ijo.2023.5550","volume":"63","author":"A Affolter","year":"2023","unstructured":"Affolter A, Liebel K, Tengler L, Seiz E, Tiedtke M, Azhakesan A, et al. Modulation of PD-L1 expression by standard therapy in head and neck cancer cell lines and exosomes. Int J Oncol. 2023;63:102.","journal-title":"Int J Oncol"},{"key":"2609_CR134","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925\u201331.","journal-title":"N Engl J Med"},{"key":"2609_CR135","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2021;39:30\u20137.","journal-title":"J Clin Oncol"},{"key":"2609_CR136","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5:1276\u201382.","journal-title":"JAMA Oncol"},{"key":"2609_CR137","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2217\/fon-2022-1146","volume":"19","author":"RT Hughes","year":"2023","unstructured":"Hughes RT, Gebeyehu RR, Kalada JM, Lycan TW, Frizzell BA, Kinney RD, et al. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced\/recurrent head and neck cancer. Future Oncol. 2023;19:1523\u201334.","journal-title":"Future Oncol"},{"key":"2609_CR138","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"2609_CR139","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","volume":"6","author":"JD Schoenfeld","year":"2020","unstructured":"Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen Y-H, Catalano PS, et al. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020;6:1563\u201370.","journal-title":"JAMA Oncol"},{"key":"2609_CR140","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687\u201395.","journal-title":"J Clin Invest"},{"key":"2609_CR141","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000527697","volume":"108","author":"C Casari","year":"2023","unstructured":"Casari C, Novysedlak R, Vachtenheim J Jr, Lischke R, Strizova Z. Novel treatment options in metastatic esophageal carcinoma: checkpoint inhibitors in combination therapies. Pharmacology. 2023;108:37\u201346.","journal-title":"Pharmacology"},{"key":"2609_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02909","volume":"9","author":"H Locy","year":"2018","unstructured":"Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout SK. Immunomodulation of the tumor microenvironment: turn foe into friend. Front Immunol. 2018;9:2909.","journal-title":"Front Immunol"},{"key":"2609_CR143","first-page":"65","volume":"67","author":"FG Herrera","year":"2017","unstructured":"Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67:65\u201385.","journal-title":"CA Cancer J Clin"},{"key":"2609_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02380-0","volume":"24","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yu Y, Zhuang J, Liu R, Sun C. Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment. Mol Cancer. 2025;24:178.","journal-title":"Mol Cancer"},{"key":"2609_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091434","volume":"11","author":"T Nyui","year":"2022","unstructured":"Nyui T, Yoshino H, Nunota T, Sato Y, Tsuruga E. cGAS regulates the radioresistance of human head and neck squamous cell carcinoma cells. Cells. 2022;11:1434.","journal-title":"Cells"},{"key":"2609_CR146","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41:843\u201352.","journal-title":"Immunity"},{"key":"2609_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914900","volume":"24","author":"S Zahnreich","year":"2023","unstructured":"Zahnreich S, El Guerzyfy S, Kaufmann J, Schmidberger H. The cGAS\/STING\/IFN-1 response in squamous head and neck cancer cells after genotoxic challenges and abrogation of the ATR-Chk1 and Fanconi anemia axis. Int J Mol Sci. 2023;24:14900.","journal-title":"Int J Mol Sci"},{"key":"2609_CR148","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/2767-9764.CRC-23-0299","volume":"4","author":"EL Saulters","year":"2024","unstructured":"Saulters EL, Kennedy PT, Carter RJ, Alsufyani A, Jones TM, Woolley JF, et al. Differential Regulation of the STING Pathway in Human Papillomavirus-Positive and -Negative Head and Neck Cancers. Cancer Res Commun. 2024;4:118\u201333.","journal-title":"Cancer Res Commun"},{"issue":"8","key":"2609_CR149","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"9","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;9(8):15618.","journal-title":"Nat Commun"},{"key":"2609_CR150","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.2147\/JIR.S497295","volume":"18","author":"L Chen","year":"2025","unstructured":"Chen L, Lin J, Wen Y, Guo ZQ, Lan B, Xiong J, et al. DNA-PKcs Dysfunction Enhances the Antitumor Activity of Radioimmunotherapy by Activating the cGAS-STING Pathway in HNSCC. J Inflamm Res. 2025;18:4177\u201393.","journal-title":"J Inflamm Res"},{"key":"2609_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104298","volume":"362","author":"VM Kho","year":"2021","unstructured":"Kho VM, Mekers VE, Span PN, Bussink J, Adema GJ. Radiotherapy and cGAS\/STING signaling: impact on MDSCs in the tumor microenvironment. Cell Immunol. 2021;362:104298.","journal-title":"Cell Immunol"},{"key":"2609_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1470468","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang Y, Mu P, Zhu X, Dong Y. Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy. Front Immunol. 2024;15:1470468.","journal-title":"Front Immunol"},{"key":"2609_CR153","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22:450\u201362.","journal-title":"Lancet Oncol"},{"key":"2609_CR154","unstructured":"Medthority. Merck KGaA and Pfizer agree to terminate the Javelin Head and Neck 100 trial of Bavencio as unlikely to show a statistically significant improvement in progression-free survival. Published March 2020. https:\/\/www.medthority.com\/news\/2020\/03\/-merck-kgaa-and-pfizer-agree-to-terminate-the-javelin-head-and-neck-100-trial-of-bavencio--as-unlikely-to-show-a-statistically-significant-improvement-in-progression-free-survival\/?utm_source=chatgpt.com Accessed 30 April 2025."},{"key":"2609_CR155","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"JP Machiels","year":"2024","unstructured":"Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25:572\u201387.","journal-title":"Lancet Oncol"},{"key":"2609_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.029","volume":"33","author":"J-P Machiels","year":"2022","unstructured":"Machiels J-P, Tao Y, Burtness B, Tahara M, Rischin D, Alves GV, et al. Primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs. placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022;33:S1399.","journal-title":"Ann Oncol"},{"key":"2609_CR157","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.anl.2024.05.001","volume":"51","author":"S Okano","year":"2024","unstructured":"Okano S. Immunotherapy for head and neck cancer: fundamentals and therapeutic development. Auris Nasus Larynx. 2024;51:684\u201395.","journal-title":"Auris Nasus Larynx"},{"key":"2609_CR158","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918768240","volume":"10","author":"EC Ko","year":"2018","unstructured":"Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: a winning new combination? Ther Adv Med Oncol. 2018;10:1758835918768240.","journal-title":"Ther Adv Med Oncol"},{"key":"2609_CR159","doi-asserted-by":"crossref","unstructured":"Riaz N, Alban TJ, Haddad RI, Saul M, Makarov V, Zhu Y, et al. Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer. Nat Cancer. 2026; In Press.","DOI":"10.1038\/s43018-025-01068-0"},{"key":"2609_CR160","doi-asserted-by":"publisher","unstructured":"Silver NL, Dai J, Kerr TD, Altemus J, Garg R, Simmons H, et al. Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma. Nat Cancer. 2026:https:\/\/doi.org\/10.1038\/s43018-025-01067-1.","DOI":"10.1038\/s43018-025-01067-1"},{"key":"2609_CR161","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C, et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct Target Ther. 2023;8:205.","journal-title":"Signal Transduct Target Ther"},{"key":"2609_CR162","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005248","volume":"10","author":"LL van der Woude","year":"2022","unstructured":"van der Woude LL, Gorris MAJ, Wortel IMN, Creemers JHA, Verrijp K, Monkhorst K, et al. Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab -radiotherapy combination. J Immunother Cancer. 2022;10:e005248.","journal-title":"J Immunother Cancer"},{"key":"2609_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205232","volume":"13","author":"JK Nam","year":"2021","unstructured":"Nam JK, Kim JH, Park MS, Kim EH, Kim J, Lee YJ. Radiation-induced fibrotic tumor microenvironment regulates anti-tumor immune response. Cancers (Basel). 2021;13:5232.","journal-title":"Cancers (Basel)"},{"key":"2609_CR164","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00109-016-1401-8","volume":"94","author":"Y Ma","year":"2016","unstructured":"Ma Y, Yang H, Pitt JM, Kroemer G, Zitvogel L. Therapy-induced microenvironmental changes in cancer. J Mol Med (Berl). 2016;94:497\u2013508.","journal-title":"J Mol Med (Berl)"},{"key":"2609_CR165","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"2609_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104905","volume":"214","author":"T Li","year":"2025","unstructured":"Li T, Gao S, Dong D, Chen Y, Li S. Research progress and future perspectives of prodrug strategies for immune checkpoint inhibitors in cancer immunotherapy. Crit Rev Oncol Hematol. 2025;214:104905.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2609_CR167","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359:1366\u201370.","journal-title":"Science"},{"key":"2609_CR168","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20:321\u201334.","journal-title":"Nat Rev Immunol"},{"key":"2609_CR169","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","volume":"16","author":"X Sun","year":"2021","unstructured":"Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, et al. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16:1260\u201370.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"2609_CR170","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","volume":"25","author":"JB Hines","year":"2023","unstructured":"Hines JB, Kacew AJ, Sweis RF. The development of STING agonists and emerging results as a cancer immunotherapy. Curr Oncol Rep. 2023;25(3):189\u201399.","journal-title":"Curr Oncol Rep"},{"key":"2609_CR171","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002852","volume":"9","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J ImmunoTher Cancer. 2021;9:e002852.","journal-title":"J ImmunoTher Cancer"},{"key":"2609_CR172","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9366","volume":"16","author":"L Chibaya","year":"2024","unstructured":"Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, et al. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024;16:eadj9366.","journal-title":"Sci Transl Med"},{"key":"2609_CR173","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-17-2807","volume":"24","author":"YS Tan","year":"2018","unstructured":"Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, et al. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clin Cancer Res. 2018;24:4242\u201355.","journal-title":"Clin Cancer Res"},{"key":"2609_CR174","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/cells10102734","volume":"10","author":"JY Jung","year":"2021","unstructured":"Jung JY, Ryu HJ, Lee SH, Kim DY, Kim MJ, Lee EJ, et al. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model. Cells. 2021;10:2734.","journal-title":"Cells"},{"key":"2609_CR175","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1038\/s41467-022-31926-9","volume":"13","author":"M Reda","year":"2022","unstructured":"Reda M, Ngamcherdtrakul W, Nelson MA, Siriwon N, Wang R, Zaidan HY, et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat Commun. 2022;13:4261.","journal-title":"Nat Commun"},{"key":"2609_CR176","doi-asserted-by":"publisher","first-page":"589959","DOI":"10.3389\/fchem.2020.589959","volume":"8","author":"ML Guevara","year":"2020","unstructured":"Guevara ML, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front Chem. 2020;8:589959.","journal-title":"Front Chem"},{"key":"2609_CR177","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409559121","volume":"122","author":"YS Cho","year":"2025","unstructured":"Cho YS, Zhou X, Sun X, Wan Z, Crowther J, Takahashi M, et al. Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle. Proc Natl Acad Sci U S A. 2025;122:e2409559121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2609_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112303","volume":"42","author":"BR Heath","year":"2023","unstructured":"Heath BR, Gong W, Taner HF, Broses L, Okuyama K, Cheng W, et al. Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. Cell Rep. 2023;42:112303.","journal-title":"Cell Rep"},{"key":"2609_CR179","doi-asserted-by":"crossref","unstructured":"Gong W, Taner HF, Wu Y, He Y, Zhou X, Li Z, et al. BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity. Nat Commun. 2025; In Press.","DOI":"10.1038\/s41467-025-68027-2"},{"issue":"Suppl 2","key":"2609_CR180","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.4103\/JPBS.JPBS_31_19","volume":"11","author":"SP Mohan","year":"2019","unstructured":"Mohan SP, Bhaskaran MK, George AL, Thirutheri A, Somasundaran M, Pavithran A. Immunotherapy in Oral Cancer. J Pharm Bioallied Sci. 2019;11(Suppl 2):S107\u201311.","journal-title":"J Pharm Bioallied Sci"},{"key":"2609_CR181","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1172\/JCI129497","volume":"130","author":"X Luo","year":"2020","unstructured":"Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, et al. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest. 2020;130:1635\u201352.","journal-title":"J Clin Invest"},{"key":"2609_CR182","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3390\/v15061296","volume":"15","author":"JP Conarty","year":"2023","unstructured":"Conarty JP, Wieland A. The tumor-specific immune landscape in HPV+ head and neck cancer. Viruses. 2023;15:1296.","journal-title":"Viruses"},{"key":"2609_CR183","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89829","volume":"1","author":"R Mandal","year":"2016","unstructured":"Mandal R, \u015eenbabao\u011flu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1:e89829.","journal-title":"JCI Insight"},{"key":"2609_CR184","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","volume":"12","author":"AT Ruffin","year":"2021","unstructured":"Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021;12:3349.","journal-title":"Nat Commun"},{"key":"2609_CR185","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","volume":"125","author":"CJ Melief","year":"2015","unstructured":"Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125:3401\u201312.","journal-title":"J Clin Invest"},{"key":"2609_CR186","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00262-020-02754-x","volume":"70","author":"S Peng","year":"2021","unstructured":"Peng S, Tan M, Li YD, Cheng MA, Farmer E, Ferrall L, et al. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. Cancer Immunol Immunother. 2021;70:1049\u201362.","journal-title":"Cancer Immunol Immunother"},{"key":"2609_CR187","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5:67\u201373.","journal-title":"JAMA Oncol"},{"key":"2609_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004232","volume":"10","author":"LG Sousa","year":"2022","unstructured":"Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, et al. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022;10:e004232.","journal-title":"J Immunother Cancer"},{"key":"2609_CR189","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-22-1987","volume":"29","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal C, Saba NF, Algazi A, Sukari A, Seiwert TY, Haigentz M, et al. Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023;29:560\u201370.","journal-title":"Clin Cancer Res"},{"key":"2609_CR190","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.oraloncology.2019.03.012","volume":"92","author":"AM Hong","year":"2019","unstructured":"Hong AM, Ferguson P, Dodds T, Jones D, Li M, Yang J, et al. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. Oral Oncol. 2019;92:33\u20139.","journal-title":"Oral Oncol"},{"key":"2609_CR191","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.3390\/ijms21155228","volume":"21","author":"N Wuerdemann","year":"2020","unstructured":"Wuerdemann N, G\u00fcltekin SE, P\u00fctz K, Wittekindt C, Huebbers CU, Sharma SJ, et al. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. Int J Mol Sci. 2020;21:5228.","journal-title":"Int J Mol Sci"},{"key":"2609_CR192","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","volume":"73","author":"S Lyford-Pike","year":"2013","unstructured":"Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733\u201341.","journal-title":"Cancer Res"},{"key":"2609_CR193","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","volume":"73","author":"C Badoual","year":"2013","unstructured":"Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128\u201338.","journal-title":"Cancer Res"},{"key":"2609_CR194","unstructured":"Flaherty C, et al. Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC. OncLive \u00ae. https:\/\/www.onclive.com\/view\/versamune-hpv-could-bolster-long-term-efficacy-with-pembrolizumab-in-hpv16-driven-hnscc?utm_source=chatgpt.com. Accessed: 30 April 2025."},{"key":"2609_CR195","doi-asserted-by":"crossref","unstructured":"Cohen EE, Moore KN, Slomovitz BM, Chung CH, Anderson ML, Morris SR, et al. Phase I\/II study of ADXS11\u2013001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent\/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. J Immunother Cancer. 2015;3(suppl 2): abstract P147.","DOI":"10.1186\/2051-1426-3-S2-P147"},{"key":"2609_CR196","doi-asserted-by":"crossref","unstructured":"Krupar R, Imai N, Miles B, Genden E, Misiukiewicz K, Saegner Y, et al. HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11\u2013001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity. Cancer Res. 2016;76(14 suppl): abstract LB-095.","DOI":"10.1158\/1538-7445.AM2016-LB-095"},{"key":"2609_CR197","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"2609_CR198","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647:488\u201397.","journal-title":"Nature"},{"key":"2609_CR199","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658\u201370.","journal-title":"Nat Biotechnol"},{"key":"2609_CR200","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/diseases10030052","volume":"10","author":"C Heini\u00f6","year":"2022","unstructured":"Heini\u00f6 C, Clubb J, Kudling T, Quixabeira D, Cervera-Carrascon V, Havunen R, et al. Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. Diseases. 2022;10:52.","journal-title":"Diseases"},{"key":"2609_CR201","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003721","volume":"10","author":"BJ Hwang","year":"2022","unstructured":"Hwang BJ, Tsao LC, Acharya CR, Trotter T, Agarwal P, Wei J, et al. Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. J Immunother Cancer. 2022;10:e003721.","journal-title":"J Immunother Cancer"},{"key":"2609_CR202","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"2609_CR203","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","volume":"25","author":"A Rosewell Shaw","year":"2017","unstructured":"Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. Mol Ther. 2017;25:2440\u201351.","journal-title":"Mol Ther"},{"key":"2609_CR204","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348.","journal-title":"Nat Med"},{"key":"2609_CR205","doi-asserted-by":"publisher","first-page":"1288383","DOI":"10.3389\/fonc.2023.1288383","volume":"13","author":"R Chen","year":"2023","unstructured":"Chen R, Chen L, Wang C, Zhu H, Gu L, Li Y, et al. CAR-T treatment for cancer: prospects and challenges. Front Oncol. 2023;13:1288383.","journal-title":"Front Oncol"},{"key":"2609_CR206","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"2609_CR207","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41557-023-01280-4","volume":"15","author":"PA Szijj","year":"2023","unstructured":"Szijj PA, Gray MA, Ribi MK, Bahou C, Nogueira JCF, Bertozzi CR, et al. Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer. Nat Chem. 2023;15:1636\u201347.","journal-title":"Nat Chem"},{"key":"2609_CR208","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"2609_CR209","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231519","volume":"221","author":"L Wang","year":"2024","unstructured":"Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024;221:e20231519.","journal-title":"J Exp Med"},{"key":"2609_CR210","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jacs.0c10008","volume":"143","author":"AD Cotton","year":"2021","unstructured":"Cotton AD, Nguyen DP, Gramespacher JA, Seiple IB, Wells JA. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J Am Chem Soc. 2021;143:593\u20138.","journal-title":"J Am Chem Soc"},{"key":"2609_CR211","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02697","volume":"9","author":"SM Jensen","year":"2018","unstructured":"Jensen SM, Potts GK, Ready DB, Patterson MJ. Specific MHC-I peptides are induced using PROTACs. Front Immunol. 2018;9:2697.","journal-title":"Front Immunol"},{"key":"2609_CR212","doi-asserted-by":"publisher","first-page":"10589","DOI":"10.1021\/acs.jmedchem.3c02259","volume":"67","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhang Y, Feng Z, Shuai M, Ma X, Wang S, et al. Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy. J Med Chem. 2024;67:10589\u2013600.","journal-title":"J Med Chem"},{"key":"2609_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114871","volume":"163","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhang Y, Su S, Tamukong P, Murali R, Kim HL. Stimulation of antitumor immunity by FoxP3-targeting PROTAC. Biomed Pharmacother. 2023;163:114871.","journal-title":"Biomed Pharmacother"},{"key":"2609_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115113","volume":"202","author":"W Chen","year":"2022","unstructured":"Chen W, Huang Y, Pan W, Xu M, Chen L. Strategies for developing PD-1 inhibitors and future directions. Biochem Pharmacol. 2022;202:115113.","journal-title":"Biochem Pharmacol"},{"key":"2609_CR215","doi-asserted-by":"publisher","first-page":"325","DOI":"10.20892\/j.issn.2095-3941.2016.0068","volume":"13","author":"GY Wan","year":"2016","unstructured":"Wan GY, Liu Y, Chen BW, Liu YY, Wang YS, Zhang N. Recent advances of sonodynamic therapy in cancer treatment. Cancer Biol Med. 2016;13:325\u201338.","journal-title":"Cancer Biol Med"},{"key":"2609_CR216","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1080\/10717544.2022.2058653","volume":"29","author":"J Zheng","year":"2022","unstructured":"Zheng J, Sun Y, Long T, Yuan D, Yue S, Zhang N, et al. Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation. Drug Deliv. 2022;29:1164\u201375.","journal-title":"Drug Deliv"},{"key":"2609_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215592","volume":"532","author":"KM Nowak","year":"2022","unstructured":"Nowak KM, Schwartz MR, Breza VR, Price RJ. Sonodynamic therapy: rapid progress and new opportunities for non-invasive tumor cell killing with sound. Cancer Lett. 2022;532:215592.","journal-title":"Cancer Lett"},{"key":"2609_CR218","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.3390\/cancers13246184","volume":"13","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Kitahara S, Kusuda K, Okamoto J, Horise Y, Masamune K, et al. Current Landscape of Sonodynamic Therapy for Treating Cancer. Cancers (Basel). 2021;13:6184.","journal-title":"Cancers (Basel)"},{"key":"2609_CR219","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ultrasmedbio.2014.05.007","volume":"40","author":"S Wang","year":"2014","unstructured":"Wang S, Hu Z, Wang X, Gu C, Gao Z, Cao W, et al. 5-Aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts. Ultrasound Med Biol. 2014;40:2125\u201333.","journal-title":"Ultrasound Med Biol"},{"key":"2609_CR220","first-page":"2163","volume":"40","author":"Y Peng","year":"2018","unstructured":"Peng Y, Jia L, Wang S, Cao W, Zheng J. Sonodynamic therapy improves anti\u2011tumor immune effect by increasing the infiltration of CD8+ T cells and altering tumor blood vessels in murine B16F10 melanoma xenograft. Oncol Rep. 2018;40:2163\u201370.","journal-title":"Oncol Rep"},{"key":"2609_CR221","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250\u20134.","journal-title":"Nature"},{"key":"2609_CR222","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9:eaak9679.","journal-title":"Sci Transl Med"},{"key":"2609_CR223","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2021.06.003","volume":"517","author":"H Nesbitt","year":"2021","unstructured":"Nesbitt H, Logan K, Thomas K, Callan B, Gao J, McKaig T, et al. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer Lett. 2021;517:88\u201395.","journal-title":"Cancer Lett"},{"key":"2609_CR224","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.ccell.2023.08.014","volume":"41","author":"V Ferrari","year":"2023","unstructured":"Ferrari V, Lo Cascio A, Melacarne A, Tanaskovi\u0107 N, Mozzarelli AM, Tiraboschi L, et al. Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I. Cancer Cell. 2023;41:1717-30.e4.","journal-title":"Cancer Cell"},{"key":"2609_CR225","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","volume":"25","author":"BA Helmink","year":"2019","unstructured":"Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25:377\u201388.","journal-title":"Nat Med"},{"key":"2609_CR226","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137.","journal-title":"Science"},{"key":"2609_CR227","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079\u201384.","journal-title":"Science"},{"key":"2609_CR228","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","volume":"5","author":"K Han","year":"2021","unstructured":"Han K, Nam J, Xu J, Sun X, Huang X, Animasahun O, et al. Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat Biomed Eng. 2021;5:1377\u201388.","journal-title":"Nat Biomed Eng"},{"key":"2609_CR229","doi-asserted-by":"crossref","unstructured":"Galizia1 D, Minei S, Abbona A, Paccagnella M, Piccinno G, Polidori A, et al. 869P Microbiota and cytokines pro le in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R\/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +\/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study. Ann Oncol. 2023;34:S560.","DOI":"10.1016\/j.annonc.2023.09.2009"},{"key":"2609_CR230","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2020.05.048","volume":"182","author":"S Kitamoto","year":"2020","unstructured":"Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gillilland MG 3rd, Hayashi A, Imai J, et al. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell. 2020;182:447-62.e14.","journal-title":"Cell"},{"key":"2609_CR231","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.mucimm.2023.11.006","volume":"17","author":"K Yamazaki","year":"2024","unstructured":"Yamazaki K, Kamada N. Exploring the oral-gut linkage: interrelationship between oral and systemic diseases. Mucosal Immunol. 2024;17:147\u201353.","journal-title":"Mucosal Immunol"},{"key":"2609_CR232","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244276","volume":"16","author":"K Okuyama","year":"2024","unstructured":"Okuyama K, Yanamoto S. Saliva in balancing oral and systemic health, oral cancer, and beyond: a narrative review. Cancers (Basel). 2024;16:4276.","journal-title":"Cancers (Basel)"},{"key":"2609_CR233","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1177\/00220345241262759","volume":"103","author":"XX Wang","year":"2024","unstructured":"Wang XX, Liu YT, Ren JG, Liu HM, Fu Q, Yang Y, et al. Salivary Microbiome Relates to Neoadjuvant Immunotherapy Response in OSCC. J Dent Res. 2024;103:988\u201398.","journal-title":"J Dent Res"},{"key":"2609_CR234","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002332","volume":"9","author":"JU Choi","year":"2021","unstructured":"Choi JU, Lee NK, Seo H, Chung SW, Al-Hilal TA, Park SJ, et al. Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia. J Immunother Cancer. 2021;9:e002332.","journal-title":"J Immunother Cancer"},{"key":"2609_CR235","doi-asserted-by":"publisher","first-page":"C10","DOI":"10.1152\/ajpcell.00158.2022","volume":"324","author":"KE Lee","year":"2023","unstructured":"Lee KE. Hypoxia as a regulator of tumor stroma and metastasis. Am J Physiol Cell Physiol. 2023;324:C10\u20133.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2609_CR236","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","volume":"352","author":"EB Rankin","year":"2016","unstructured":"Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175\u201380.","journal-title":"Science"},{"key":"2609_CR237","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/hed.25366","volume":"40","author":"Y Takenaka","year":"2018","unstructured":"Takenaka Y, Oya R, Kitamiura T, Ashida N, Shimizu K, Takemura K, et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis. Head Neck. 2018;40:2714\u201323.","journal-title":"Head Neck"},{"key":"2609_CR238","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0065-5","volume":"7","author":"S Rachidi","year":"2014","unstructured":"Rachidi S, Wallace K, Day TA, Alberg AJ, Li Z. Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. J Hematol Oncol. 2014;7:65.","journal-title":"J Hematol Oncol"},{"key":"2609_CR239","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00432-009-0625-1","volume":"135","author":"MH Chen","year":"2009","unstructured":"Chen MH, Chang PM, Chen PM, Tzeng CH, Chu PY, Chang SY, et al. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. J Cancer Res Clin Oncol. 2009;135:1783\u201390.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2609_CR240","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/ijc.29870","volume":"138","author":"S Shoultz-Henley","year":"2016","unstructured":"Shoultz-Henley S, Garden AS, Mohamed AS, Sheu T, Kroll MH, Rosenthal DI, et al. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. Int J Cancer. 2016;138:1290\u20137.","journal-title":"Int J Cancer"},{"key":"2609_CR241","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/CMAR.S234618","volume":"12","author":"J Ye","year":"2020","unstructured":"Ye J, Liao B, Jiang X, Dong Z, Hu S, Liu Y, et al. Prognosis Value of Platelet Counts, Albumin and Neutrophil-Lymphocyte Ratio of Locoregional Recurrence in Patients with Operable Head and Neck Squamous Cell Carcinoma. Cancer Manag Res. 2020;12:731\u201341.","journal-title":"Cancer Manag Res"},{"key":"2609_CR242","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s00262-023-03392-9","volume":"72","author":"M Li","year":"2023","unstructured":"Li M, Zhao S, Lopez G, Secor A, Das P, Surya N, et al. Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy. Cancer Immunol Immunother. 2023;72:2067\u201374.","journal-title":"Cancer Immunol Immunother"},{"key":"2609_CR243","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1940-6207.CAPR-09-0151","volume":"3","author":"DL McCormick","year":"2010","unstructured":"McCormick DL, Phillips JM, Horn TL, Johnson WD, Steele VE, Lubet RA. Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev Res (Phila). 2010;3:73\u201381.","journal-title":"Cancer Prev Res (Phila)"},{"key":"2609_CR244","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/gutjnl-2020-320946","volume":"70","author":"L Reyes-Uribe","year":"2021","unstructured":"Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, et al. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut. 2021;70:555\u201366.","journal-title":"Gut"},{"key":"2609_CR245","doi-asserted-by":"publisher","first-page":"eaay4860","DOI":"10.1126\/scitranslmed.aay4860","volume":"12","author":"A Metelli","year":"2020","unstructured":"Metelli A, Wu BX, Riesenberg B, Guglietta S, Huck JD, Mills C, et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2. Sci Transl Med. 2020;12:eaay4860.","journal-title":"Sci Transl Med"},{"key":"2609_CR246","doi-asserted-by":"publisher","first-page":"12554","DOI":"10.18632\/oncotarget.23792","volume":"9","author":"J Mart\u00edn-L\u00f3pez","year":"2017","unstructured":"Mart\u00edn-L\u00f3pez J, Gasparini P, Coombes K, Croce CM, Boivin GP, Fishel R. Mutation of TGF\u03b2-RII eliminates NSAID cancer chemoprevention. Oncotarget. 2017;9:12554\u201361.","journal-title":"Oncotarget"},{"key":"2609_CR247","doi-asserted-by":"publisher","first-page":"2466308","DOI":"10.1080\/2162402X.2025.2466308","volume":"14","author":"DA Ruiz-Torres","year":"2025","unstructured":"Ruiz-Torres DA, Bryan ME, Hirayama S, Merkin RD, Luciani E, Roberts TJ, et al. Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma. Oncoimmunology. 2025;14:2466308.","journal-title":"Oncoimmunology"},{"key":"2609_CR248","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1940-6207.CAPR-22-0511","volume":"16","author":"K Okuyama","year":"2023","unstructured":"Okuyama K, Yanamoto S. Oral bacterial contributions to gingival carcinogenesis and progression. Cancer Prev Res (Phila). 2023;16:199\u2013209.","journal-title":"Cancer Prev Res (Phila)"},{"key":"2609_CR249","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02405-2","volume":"41","author":"K Okuyama","year":"2022","unstructured":"Okuyama K, Yanamoto S. TMEM16A as a potential treatment target for head and neck cancer. J Exp Clin Cancer Res. 2022;41:196.","journal-title":"J Exp Clin Cancer Res"},{"key":"2609_CR250","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1200\/JCO.20.00201","volume":"38","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebb\u00e9 C, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020;38:2476\u201387.","journal-title":"J Clin Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02609-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:03:10Z","timestamp":1777575790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":250,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2609"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02609-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}